These results indicate that the presence of TP53 mutations in CAFs is limited to certain tumor entities such as breast and colon whereas CAFs from other entities such as lung remain wild type TP53. This would imply that the reaction of CAFs to cytotoxic agents and their influence on therapy response are fundamentally different in different organs. The gene discussed is TP53; the disease is neoplasm.